Tredje AP fonden Decreases Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

Tredje AP fonden reduced its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 1.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,512 shares of the medical instruments supplier’s stock after selling 182 shares during the period. Tredje AP fonden’s holdings in West Pharmaceutical Services were worth $3,792,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Fidelis Capital Partners LLC purchased a new stake in shares of West Pharmaceutical Services in the first quarter worth about $27,000. Crewe Advisors LLC lifted its position in West Pharmaceutical Services by 322.7% during the 2nd quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 71 shares in the last quarter. Quarry LP boosted its holdings in West Pharmaceutical Services by 155.3% in the 4th quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock worth $34,000 after acquiring an additional 59 shares during the period. Hazlett Burt & Watson Inc. acquired a new stake in West Pharmaceutical Services in the first quarter valued at approximately $40,000. Finally, Northwest Investment Counselors LLC purchased a new stake in shares of West Pharmaceutical Services during the first quarter valued at approximately $40,000. 93.90% of the stock is owned by hedge funds and other institutional investors.

West Pharmaceutical Services Price Performance

Shares of WST stock opened at $309.20 on Thursday. The firm has a fifty day simple moving average of $304.36 and a 200-day simple moving average of $338.16. The company has a market capitalization of $22.43 billion, a PE ratio of 40.79, a price-to-earnings-growth ratio of 10.58 and a beta of 1.01. West Pharmaceutical Services, Inc. has a twelve month low of $265.00 and a twelve month high of $413.70. The company has a current ratio of 2.34, a quick ratio of 1.68 and a debt-to-equity ratio of 0.03.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). The firm had revenue of $702.10 million during the quarter, compared to analyst estimates of $729.36 million. West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The business’s quarterly revenue was down 6.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.11 EPS. Equities research analysts anticipate that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current fiscal year.

Insider Activity at West Pharmaceutical Services

In other West Pharmaceutical Services news, VP Charles Witherspoon sold 1,029 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $300.00, for a total transaction of $308,700.00. Following the sale, the vice president now directly owns 1,478 shares in the company, valued at approximately $443,400. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.53% of the stock is currently owned by company insiders.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.